SlidesetHIVTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #10 Drug Interactions Between Probe Drugs Dolutegravir (DTG), Midazolam (MDZ) and Digoxin (DIG) with Escalating Doses of Rifampicin (RIF): DORIS Study - Laura DickinsonView Slideset
SlidesetTuberculosis26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #9 Physiologically Based Pharmacokinetic Modeling to Inform Lenacapavir Dose Regimen When Co-Administered with Rifamycins in Participants with Tuberculosis - Sara SalernoView Slideset
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #8 Pharmacogenetic and Pharmacokinetic Profiling of Bulevirtide in Patients with Chronic Hepatitis D: A Preliminary Study - Jessica CusatoView Slideset
JCJessica CusatoBSc, MSc, PhDSlidesetViral Hepatitis and Liver Disease26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Pharmacology of HDV - Jessica CusatoView Slideset
KWCKeith W. CrawfordRPh, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025NIH Initiatives and Research Promoting Antiviral Pharmacology - Keith W. CrawfordView Slideset
Slideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #7 An Enzymatic Assay for Rapid and Minimally Instrumented Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus - Willow ChernoskeView Slideset
Slideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #6 Target Attainment of Valganciclovir Prophylaxis against Cytomegalovirus - Suzanne WenkerView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #5 Plasma Bictegravir/Emtricitabine/Tenofovir Alafenamide Concentrations in Transgender Women with HIV on Estrogen-Based Gender-Affirming Hormone Therapy in Comparison to Cisgender Women Living with HIV - Shawnalyn SunagawaView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #4 Pharmacokinetic Parameters of Bictegravir in Breastmilk of Healthy, Lactating Volunteers without HIV After a Single Dose of 50mg (Co-Formulated with Emtricitabine 200mg and Tenofovir Alafenamide 25mg) - Lena Christina Wendy van der Wekken-PasView Slideset
SlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025Abstract #3 Therapeutic Drug Monitoring of Dolutegravir in Children and Adolescents Living with HIV: A Retrospective Study - Émilie PiloteView Slideset
AOAdeniyi OlagunjuBPharm, MRes, PhDSlideset26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025New Models for Drug Exposure and Safety During Pregnancy - Adeniyi OlagunjuView Slideset
STSteve TaylorMBChB, FRCP, PhDSlidesetHIV26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2025HIV PEP in Clinical Practice: Guidelines and Real-World Complexities - Steve TaylorView Slideset
